ABT has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ABT has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Abbott Laboratories's enterprise value is $206,666 Mil. Abbott Laboratories's EBITDA for the trailing twelve months (TTM) ended in Jun. 2024 was $9,333 Mil. Therefore, Abbott Laboratories's EV-to-EBITDA for today is 22.14.
The historical rank and industry rank for Abbott Laboratories's EV-to-EBITDA or its related term are showing as below:
During the past 13 years, the highest EV-to-EBITDA of Abbott Laboratories was 29.25. The lowest was 12.15. And the median was 19.85.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2024-10-31), Abbott Laboratories's stock price is $113.37. Abbott Laboratories's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 was $3.290. Therefore, Abbott Laboratories's PE Ratio (TTM) for today is 34.46.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
The historical data trend for Abbott Laboratories's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Abbott Laboratories Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
EV-to-EBITDA | Get a 7-Day Free Trial | 21.65 | 23.37 | 20.95 | 16.37 | 18.92 |
Abbott Laboratories Quarterly Data | ||||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
EV-to-EBITDA | Get a 7-Day Free Trial | 17.58 | 18.92 | 20.61 | 19.78 | - |
For the Medical Devices subindustry, Abbott Laboratories's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Devices & Instruments industry and Healthcare sector, Abbott Laboratories's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Abbott Laboratories's EV-to-EBITDA falls into.
Abbott Laboratories's EV-to-EBITDA for today is calculated as:
EV-to-EBITDA | = | Enterprise Value (Today) | / | EBITDA (TTM) |
= | 206666.212 | / | 9333 | |
= | 22.14 |
Abbott Laboratories's current Enterprise Value is $206,666 Mil.
Abbott Laboratories's EBITDA for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $9,333 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Abbott Laboratories (NYSE:ABT) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Abbott Laboratories's PE Ratio (TTM) for today is calculated as:
PE Ratio (TTM) | = | Share Price (Today) | / | Earnings per Share (Diluted) (TTM) |
= | 113.37 | / | 3.290 | |
= | 34.46 |
Abbott Laboratories's share price for today is $113.37.
Abbott Laboratories's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $3.290.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
Please read Which price ratio outperforms the enterprise multiple?
Thank you for viewing the detailed overview of Abbott Laboratories's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Robert B Ford | officer: Senior Vice President | 100 ABBOTT PARK ROAD, AP6A-2, D-032L, ABBOTT PARK IL 60064-6092 |
Mccoy John A. Jr. | officer: VICE PRESIDENT | C/O ABBOTT LABORATORIES, 100 ABBOTT PARK ROAD, ABBOTT PARK IL 60064 |
Robert E Funck | officer: Vice President, Controller | 100 ABBOTT PARK ROAD, D-378, AP6D-2, ABBOTT PARK IL 60064-6092 |
Lisa D Earnhardt | officer: Executive Vice President | 1555 ADAMS DRIVE, C/O INTERSECT ENT, INC., MENLO PARK CA 94025 |
Salvadori Daniel Gesua Sive | officer: Senior Vice President | 100 ABBOTT PARK ROAD, AP6A-2, D-032L, ABBOTT PARK IL 60064-6092 |
Mary K Moreland | officer: Executive Vice President | 100 ABBOTT PARK ROAD, ABBOTT PARK IL 60064 |
Hubert L Allen | officer: Executive Vice President | 100 ABBOTT PARK ROAD, AP6C-1N, ABBOTT PARK IL 60064-6092 |
Louis H. Morrone | officer: EXECUTIVE VICE PRESIDENT | 100 ABBOTT PARK ROAD, ABBOTT PARK IL 60064 |
Andrea F Wainer | officer: Executive Vice President | 100 ABBOTT PARK ROAD, ABBOTT PARK IL 60064 |
Daniel J Starks | director | ONE ST JUDE MEDICAL DRIVE, ST PAUL MN 55117 |
Michael F Roman | director | 3M COMPANY OFFICE OF GENERAL COUNSEL, 3M CENTER, ST. PAUL MN 55144-1000 |
Patricia Paola Gonzalez | director | 100 ABBOTT PARK ROAD, ABBOTT PARK IL 60064 |
Philip P Boudreau | officer: Vice President | 100 ABBOTT PARK ROAD, ABBOTT PARK IL 60064 |
Michael O'grady | director | 50 S LASALLE STREET, CHICAGO IL 60603 |
Gregory A Ahlberg | officer: Senior Vice President | 100 ABBOTT PARK ROAD, ABBOTT PARK IL 60064 |
From GuruFocus
By PRNewswire • 09-05-2024
By ACCESSWIRE • 09-12-2024
By PRNewswire • 09-19-2024
By GuruFocus Research • 08-05-2024
By ACCESSWIRE • 07-24-2024
By PRNewswire • 09-25-2024
By GuruFocus Research • 07-25-2024
By PRNewswire • 06-27-2024
By GuruFocus Research • 08-21-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.